Biosana to work collaboratively with the Bioprocessing Technology Institute, aiming to design a highly flexible and cost-effective continuous manufacturing solution.
The abundance of data made available by continuous bioprocessing allows for more control over the process and can thereby improve the quality of the product, says Pall executive.
At the BIA’s annual conference, industry executives discussed the UK’s position as a leader in bioprocessing and what steps must be taken to keep pace with global innovation.
Sanofi opens its Massachusetts, US-based facility that will use digital technology for continuous biologic production, with similar plants planned in Canada, Brazil, Ireland, France, and Belgium.
